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a  b  s  t  r  a  c  t
Introduction: The previous radio-chemotherapy approach is highly relevant in the manage-
ment of rectal cancer, collaborating on organ functional preservation, being performed prior
to  surgery. The inﬂammatory response plays an important role in this treatment.
Objective: It consists in correlating the number of peripheral lymphocytes and the neu-
trophil/lymphocyte ratio in the peripheral blood with tumor response to neoadjuvant
therapy.
Methods: Review of medical records of patients with rectal cancer in HMSJ and HSJ Oncology
Services since 2009 – cases submitted to neoadjuvant treatment with radio-chemotherapy.
Results: Of those 96 patients with this disease who underwent neoadjuvant therapy with
radio-chemotherapy, 35 patients were eligible; complete tumor response was observed
in  11 cases (31%), and 9 were submitted to surgical treatment. Comparing the leuko-
cyte  parameters between patients with complete response (CR) and incomplete response
(IR)  the following values were observed: total number of leukocytes (mean) CR 7390.9 × IR
7220.4 (p = 0.8); total lymphocytes CR 2103 × IR 1960.9 (p = 0.4); neutrophil/lymphocyte ratio
CR  3.55 × IR 3.79 (p = 0.5). The mean radiotherapy dose was 49.1 Gy, with CR 47.3 × IR 50.0
(p  = 0.06).
Conclusion: It was not possible to demonstrate in this study a signiﬁcant relationship
between complete tumor response to neoadjuvant therapy with respect to blood leukocyte
parameters analyzed.e Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All© 2015 Sociedadrights reserved.
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Análise  da  relac¸ão neutróﬁlo-linfócito  como  elemento  prognóstico  na







r  e  s  u  m  o
Introduc¸ão: A abordagem radio-quimioterápica previa apresenta grande relevância no manu-
seio  do câncer de reto, colaborando na preservac¸ão funcional do órgão, sendo realizada
previamente à cirurgia. A resposta inﬂamatória tem papel importante neste tratamento.
Objetivo: Consiste em correlacionar o número de linfócitos periféricos e a relac¸ão neutróﬁ-
los/linfócitos no sangue periférico com a resposta tumoral à terapia neo-adjuvante.
Métodos: Revisão de prontuários dos pacientes portadores de câncer retal dos servic¸os de
Oncologia do HMSJ e HSJ, desde 2009, casos submetidos ao tratamento neo-adjuvante com
radio-quimioterapia.
Resultados: Do total de 96 pacientes portadores desta enfermidade, submetidos à terapia
neo-adjuvante com radio-quimioterapia foram elegíveis 35 pacientes, tendo sido observada
resposta completa tumoral em 11 casos (31%), e nove foram submetidos ao tratamento
cirúrgico. Na comparac¸ão dos parâmetros leucocitários entre os pacientes com resposta
completa (RC) e resposta incompleta (RI) foram observados os seguintes valores: número
total de leucócitos (média) RC 7390,9 × RI 7220,4 (p = 0,8); linfócitos totais RC 2103 × RI 1960,9
(p  = 0,4); relac¸ão neutróﬁlo/linfócito RC 3,55 × RI 3,79 (p = 0,5). A dose radioterápica média foi
de  49.1 Gy, sendo RC 47,3 × RI 50,0 (p = 0,06).
Conclusão: Não foi possível demonstrar no presente estudo relac¸ão signiﬁcativa entre
resposta completa tumoral à terapia neo-adjuvante nos parâmetros analisados do perﬁl
leucocitário.
©  2015 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
Todos os direitos reservados.Introduction
The good results obtained with the association of chemother-
apy with radiotherapy led to the adoption of neoadjuvant
therapy in the treatment of rectal cancer, with the aim of
promoting a reduction in tumor size, allowing better condi-
tions of resectability and sphincter preservation; this has led
some authors to suggest a non-surgical treatment in cases of
complete response to neoadjuvant therapy. It was not thus far
possible to identify prognostic factors that could contribute to
the prognosis, with high levels of accuracy, to the occurrence
of tumor regression in response to neoadjuvant therapy.
On the other hand, several studies have suggested that
the host immune response plays a very important role in this
response. Various aspects of immunology have been the sub-
ject of studies, taking into account factors related to the tumor,
the host and their interaction. Among these factors, the most
consistent results have been obtained in the evaluation of local
and systemic lymphocytic response, characterized by lympho-
cyte inﬁltration into the tumor tissue and by a greater presence
of lymphocytes in peripheral blood. The prognostic value of
this greater systemic lymphocytic expression has been shown
by studies suggesting a better tumor response to neoadjuvant
therapy in patients who have an increased number of lympho-
cytes, in proportion to the total number of neutrophils, and
this relationship is summarized by the relationship between
neutrophils and lymphocytes.1
Therefore, the aim of this study is to analyze a possible
prognostic value of blood leukocytes in peripheral blood withtumor response to neoadjuvant therapy, observed in a group
of patients with rectal cancer.
Methods
Patients
Medical records of 96 patients with rectal cancer, treated in
the Radiotherapy Services of the Hospital Municipal São José
(HMSJ) in Joinville and of the Hospital São José (HSJ) in Jaragua
do Sul, were reviewed; these patients underwent neoadjuvant
treatment with radiotherapy and chemotherapy.
Among these participants, those with incomplete data in
their medical records (making it impossible to assess their
outcomes) were excluded, as well as patients with no com-
plete blood count (CBC) available for evaluation, patients who
did not conclude the radiochemotherapy, or who  were lost
to oncological follow-up. Thus, 35 patients (14 males) with a
mean age of 55 years were eligible.
Neoadjuvant therapy was indicated for patients with rec-
tal adenocarcinomas located in the middle and lower third
of the rectum, whose staging suggested parietal invasion
(T3 or T4 stage), or by the presence of a possible perirec-
tal lymphadenopathy. All patients underwent proctologic
examination, endoscopic assessment and biopsy through
colonoscopy or rectosigmoidoscopy, and an imaging exami-
nation by computed tomography or magnetic resonance was
obtained, in addition to a chest X-ray, to rule out metastatic
lesions.
















































Table 1 – Total number of leukocytes.
Complete response N Mean SD p
Absent 24 7220 1999.2 0.838
complete response.
Table 2 – Lymphocyte expression.
Complete response N Mean SD p
Total lymphocytes
Absent 24 1960 608.3 0.474
Present 11 2103 338.9j coloproctol (ri
eoadjuvant  therapy  technique
ll patients underwent two-dimensional radiotherapy with
imulations using contrast-enhanced radiography of the rec-
um and bladder, or three-dimensional radiotherapy with
imulations using computed tomography and intravenous
ontrast. The treatment volumes were: primary tumor and
ts local-regional lymphatic (perirectal, iliac and obturator)
rainages, with dosages from 45 to 50.40 Gy administered
ver 25–28 days, from Monday to Friday. A four-ﬁeld treat-
ent was performed; the patient was placed in a prone
osition, and the belly-board technique was used for bowel
oop removal and toxicity reduction. The patients treated
y three-dimensional technique were evaluated according to
 dose/volume histogram, and the two-dimensional treat-
ent cases were evaluated with the use of treatment
urves.
The chemotherapy procedure consisted of an infusional
hemotherapy, including 5-ﬂuorouracil (5-FU) and leucovorin
Lv) in the ﬁrst and last ﬁve days of radiotherapy; or, alterna-
ively, by continuous oral ingestion of capecitabine throughout
adiotherapy.
With respect to whether or not performing the surgical
reatment, the therapeutic conduct was deﬁned by those sur-
eons responsible for each case.
Patients undergoing surgical treatment had their tumor
esponse deﬁned by a pathological analysis of the surgical
pecimen, with the response being classiﬁed as complete or
ncomplete.
lood  leukocyte  proﬁle  analysis
he number of total leukocytes and the expression of lym-
hocytes were identiﬁed by reviewing a CBC performed before
tarting the treatment with radiotherapy and chemother-
py. The relationship between leukocytes and lymphocytes
as obtained by the following calculation: “total leukocyte
ount divided by the total number of lymphocytes” (neu-
rophil/lymphocyte ratio; N/L).
ata  procedure  and  statistical  analysis
he data were stored in an Excel database (Microsoft Ofﬁce
003 package) and analyzed with the Statistical Package for
he Social Sciences (SPSS) program, version 17.0.
thical  aspects
he study was approved by the Ethics Committee of the Uni-
ersidade da Região de Joinville (UNIVILLE). The study began
fter the Ethics Committee approval.
esults
f the 35 patients analyzed, complete (clinical or pathological)
esponses were observed in 11 cases (31.4%). In two patients,
e opted for a scheme of observation with frequent revisions
clinical response), while in nine cases surgical treatment
pathological response) was performed.Present 11 7390 2788.5
Patients  with  complete  response  who  did  not  undergo
surgery
These two patients were not submitted to surgical treat-
ment, as a complete tumor response, evaluated by digital
rectal examination and sigmoidoscopy, was observed. These
patients were followed for a median of 24 months.
In this group, the mean age was 82.5 years; one of these
patients was a man.
In this observational period, there was no evidence of
tumor recurrence in both patients.
Operated  patients
Of the 32 patients who underwent surgical resection after
neoadjuvant therapy, a complete pathological response was
observed in nine (28%). This group had a mean age of 51.9
years; among those who achieved a complete response, 48.8
years; and for those cases of tumor persistence, 55 years.
Non-operated  patients
One patient had the disease and could not be operated due
to the clinical condition. This patient was considered as not
respondent, and data were included in the analysis.
Blood  leukocyte  proﬁle  analysis
Considering the total number of patients with complete or
incomplete response to neoadjuvant therapy, we  observed
the respective blood leukocyte proﬁles for each group, as fol-
lows.
Total  number  of  leukocytes
As shown in Table 1, the CBC obtained previously to neoadju-
vant therapy showed that there was no statistical difference in
total number of leukocytes between patients with and without% Lymphocytes
Absent 24 27 6.0 0.193
Present 11 31 9.8
6  j coloproctol (rio j). 2
Table 3 – Neutrophil/lymphocyte ratio.
Complete response N Mean SD p
N/L ratio
Absent 24 3.7 0.88 0.502
Present 11 3.5 1.21
Table 4 – Radiotherapy dosage.
Complete response N Mean SD p
survival, shorter time to local recurrence and lower disease-Absent 24 50 4.4 0.065
Present 11 47 2.6
Lymphocyte  expression
As shown in Table 2, the CBC obtained previously to neoadju-
vant therapy showed that there was no statistical difference
regarding the absolute or relative number of lymphocytes
between patients with or without complete response.
Neutrophil/lymphocyte  (N/L)  ratio
As shown in Table 3, the CBC obtained previously to neoadju-
vant therapy showed that there was no statistical difference
regarding the neutrophil/lymphocyte ratio between patients
with or without complete response.
Treatment  dose
Although the radiotherapy dose was not among the variables
initially established for analysis in this study, the retrospec-
tively observed difference between the means of complete and
incomplete response groups (50 Gy × 47 Gy) led us to assess its
possible prognostic value. As shown in Table 4, a borderline
difference for signiﬁcance (p = 0.06) was observed.
Excluded  patients
After the selection of 96 patients (35 from the center of Joinville
and 61 from the center of Jaragua do Sul), 61 cases that did not
meet the criteria for inclusion in the study were excluded.
Discussion
Tumor antiinﬂammatory response plays an important role in
tumor evolution response, including cases of colorectal can-
cer. Several studies have reported that tumor inﬁltration by
CD8+ T cells, when activated, shows prognostic value and good
correlation with disease staging, suggesting a possible action
that induces tumor cell apoptosis. This lymphocyte activation
can be demonstrated by the local expression of elements such
as granzimes B, CD69+ or CD107+. According to Koch et al., an
increase in the number of CD4+ T cells was observed in the
mucous membrane of tumor cells, compared to normal tissue
mucosa, suggesting an increased immune response in colorec-
tal tumors. This prognostic value was also observed by Naito
et al.; these authors studied 131 cases of colorectal cancer and
correlated the location of CD8+ cells, which, when present in
the vicinity of the cancer cell nidus, showed better survival.2–4 0 1 5;3  5(1):3–7
In addition of tumor response, there is compelling evidence
of a relationship between systemic response and prognosis.
Several authors have shown that the number of circulating
lymphocytes, in particular through a neutrophil/lymphocyte
(N/L) ratio analysis, has prognostic value in cases of colorectal
cancer. Liu et al. noted a signiﬁcant relationship between N/L
value and survival of patients undergoing treatment of rectal
cancer. Hung et al. analyzed 1040 patients with colon cancer
(stage II), of whom 785 (75.5%) exhibited normal N/L  ratios
and 255 (24.5%) had high N/L ratios. Patients with high N/L
had lower rates of overall survival and of disease-free interval,
when compared to patients with normal N/L.5
Chiang et al. evaluated 3857 patients with colorectal can-
cer in stages I–III, noting that N/L ratios >3 were associated
with higher sensitivity and speciﬁcity and lower survival after
5 years, both in colon cancer (66.3% × 78.9%, p < 0.001) and in
colorectal cancer (60.5% × 66.2%) compared with patients with
N/L ratios below this value. Furthermore, patients with N/L
above this level also exhibited larger tumors (5 cm)  and a more
advanced local disease.6
Chua et al. analyzed 349 patients in two  independent
cohorts treated with ﬁrst-line palliative chemotherapy and
noted that N/L ratio is a positive prognostic factor.7
Relationship  between  systemic  inﬂammatory  response
and response  to  neoadjuvant  therapy  in  rectal  cancer
Once detecting the prognostic value of the systemic inﬂamma-
tory response, some authors have sought to demonstrate its
possible inﬂuence on radiochemotherapy results performed
in patients with rectal tumor. In a study that analyzed 73
patients operated for treatment of rectal cancer after neoad-
juvant radiochemotherapy, 10 (14%) achieved complete tumor
response. The authors observed a signiﬁcantly higher periph-
eral lymphocyte count (p = 0.02) and a neutrophil/lymphocyte
ratio tending to lower values (p = 0.099). Based on these ﬁnd-
ings, the authors suggested that the complete eradication of
tumor cells is dependent on an immune reaction mediated
by lymphocytes, and that the maintenance of the number
of circulating lymphocytes is an important factor in this
response to neoadjuvant therapy. The same authors, in a
subsequent study, analyzed blood samples taken before and
after radiotherapy and conﬁrmed that patients who  achieved
a complete response, with disappearance of tumor cells
(15/179), had elevated peripheral lymphocyte counts and low
neutrophil/lymphocyte ratios.8
In a study that analyzed the tumor response to
radiochemotherapy with barium enema, the authors also
observed an association between this response and the
proportion of lymphocytes in relation to leukocytes. Other
authors related the results obtained in the treatment
of rectal cancer in 115 patients undergoing neoadjuvant
therapy with the use of radiochemotherapy with the neu-
trophil/lymphocyte ratio (N/L) obtained from peripheral blood,
noting that N/L ratios >5 were associated with lower overallfree interval. Moreover, these patients showed a median
survival of 18.8 months compared with 54.4 months for those




















































In an interesting development of the ﬁndings mentioned
bove, a study was conducted in which the authors sought to
orrelate tumor response to neoadjuvant therapy in patients
ith rectal cancer with the apoptotic index obtained with
n vitro irradiation of lymphocytes obtained from peripheral
lood of these patients. As a result, these authors achieved
 signiﬁcant correlation between lymphocyte apoptosis and
istological regression, concluding that tumor radiosensiti-
ity can be estimated from the apoptotic index of lymphocytes
n vitro.10
elationship  between  lymphocytic  inﬁltration  and
esponse  to  neoadjuvant  therapy  in  rectal  cancer
ith the use of immunohistochemistry, Yasuda et al. analyzed
he level of tumor inﬁltration (LTI) by CD4+ and CD8+ T cells in
iopsies of 48 cases of advanced colorectal cancer before com-
letion of neoadjuvant radiochemotherapy, and related their
ndings to the tumor reduction evaluated by barium enema
nd by biopsy after neoadjuvant therapy. The numbers of both
D4+ and CD8+ lymphocytes in biopsy samples previously
o radiochemotherapy showed strong correlation with tumor
eduction, as assessed by barium enema. Moreover, CD4+ and
D8+ LTI densities were signiﬁcantly associated with histo-
ogical grade after neoadjuvant therapy. CD8+ LTI density was
lso an independent prognostic factor in achieving a complete
esponse.1
In the present study, the occurrence of complete tumor
esponse after neoadjuvant therapy for the treatment of rec-
al cancer was observed in 31.4% of cases, a result consistent
ith those observed in the literature. However, it was not
ossible to detect a relationship between this response and
he analyzed elements in the leukocyte proﬁle, including
he total numbers of leukocytes and lymphocytes and the
eutrophil/lymphocyte ratio. We  believe that the small num-
er of cases included in this study might have contributed
o this ﬁnding, due to factors inherent to a retrospective
tudy.
On the other hand, the strong trend for a signiﬁcant cor-
elation between the response and the dose of radiotherapy
dministered called our attention to the need for taking a pos-
ibly greater control, in order to reduce the variability between
reatments, with the establishment of more  rigid protocols for
ptimizing the neoadjuvant therapy results.
onclusions
n this study, we  could not demonstrate a signiﬁcant rela-
ionship between complete tumor response and neoadjuvant
herapy in the analyzed leukocyte proﬁle parameters, includ-
ng a previous total number of leukocytes, absolute and
elative numbers of lymphocytes, and neutrophil/lymphocyte
atio.onﬂicts  of  interest
he authors declare no conﬂicts of interest. 0 1 5;3  5(1):3–7  7
Annex.  Table  of  pathological  response  grading.
Dworak et al. (14) Rodei et al. (17)
0. No regression 0. No regression
1. Predominantly tumor with
signiﬁcant ﬁbrosis and/or
vasculopathy
1. Regression <25% of
tumor mass
2. Predominantly ﬁbrosis with
scattered tumor cells (slightly
recognizable histologically)
2. Regression of 25–50%
of tumor mass
3. Only scattered tumor cells in
the area of ﬁbrosis
with/without acellular mucin
3. Regression >50% of
tumor mass
4. No vital tumor cells detectable 4. Complete regression
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